JP2014529621A - 抗炎症性の置換シクロブテンジオン化合物のコリン塩 - Google Patents

抗炎症性の置換シクロブテンジオン化合物のコリン塩 Download PDF

Info

Publication number
JP2014529621A
JP2014529621A JP2014527801A JP2014527801A JP2014529621A JP 2014529621 A JP2014529621 A JP 2014529621A JP 2014527801 A JP2014527801 A JP 2014527801A JP 2014527801 A JP2014527801 A JP 2014527801A JP 2014529621 A JP2014529621 A JP 2014529621A
Authority
JP
Japan
Prior art keywords
dosage form
enylamino
cyclobut
propylamino
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527801A
Other languages
English (en)
Japanese (ja)
Inventor
アミート・ビジャイ・アンバーケイン
アルノー・モレー
カルステン・ティンペ
ウルス・ベティッヒ
Original Assignee
ノバルティスアーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティスアーゲー, ノバルティス アーゲー filed Critical ノバルティスアーゲー
Publication of JP2014529621A publication Critical patent/JP2014529621A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014527801A 2011-09-02 2012-08-31 抗炎症性の置換シクロブテンジオン化合物のコリン塩 Pending JP2014529621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02
US61/530,516 2011-09-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175348A Division JP6612200B2 (ja) 2011-09-02 2016-09-08 抗炎症性の置換シクロブテンジオン化合物のコリン塩

Publications (1)

Publication Number Publication Date
JP2014529621A true JP2014529621A (ja) 2014-11-13

Family

ID=47116123

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014527801A Pending JP2014529621A (ja) 2011-09-02 2012-08-31 抗炎症性の置換シクロブテンジオン化合物のコリン塩
JP2016175348A Expired - Fee Related JP6612200B2 (ja) 2011-09-02 2016-09-08 抗炎症性の置換シクロブテンジオン化合物のコリン塩
JP2018135448A Pending JP2019001787A (ja) 2011-09-02 2018-07-19 抗炎症性の置換シクロブテンジオン化合物のコリン塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016175348A Expired - Fee Related JP6612200B2 (ja) 2011-09-02 2016-09-08 抗炎症性の置換シクロブテンジオン化合物のコリン塩
JP2018135448A Pending JP2019001787A (ja) 2011-09-02 2018-07-19 抗炎症性の置換シクロブテンジオン化合物のコリン塩

Country Status (17)

Country Link
US (1) US9018261B2 (enExample)
EP (2) EP3287438A1 (enExample)
JP (3) JP2014529621A (enExample)
KR (1) KR102024955B1 (enExample)
CN (1) CN103842330B (enExample)
BR (1) BR112014004963A2 (enExample)
CA (1) CA2846510C (enExample)
EA (1) EA201490552A1 (enExample)
ES (1) ES2655942T3 (enExample)
HU (1) HUE035751T2 (enExample)
IN (1) IN2014DN02346A (enExample)
MX (1) MX359259B (enExample)
NO (1) NO2679622T3 (enExample)
PL (1) PL2760821T3 (enExample)
PT (1) PT2760821T (enExample)
SI (1) SI2760821T1 (enExample)
WO (1) WO2013030803A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508891A (ja) * 2001-01-30 2006-03-16 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 治療上有効な成分の長期放出／持続放出のための医薬組成物
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
WO2010015613A1 (en) * 2008-08-04 2010-02-11 Novartis Ag Organic compounds
WO2010057036A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
ES2128774T3 (es) 1994-11-16 1999-05-16 American Home Prod Diaminociclobuten-3,4-dionas.
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
WO2002062761A1 (en) 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
KR20030088044A (ko) 2001-03-30 2003-11-15 스미스클라인 비참 코포레이션 페놀-함유 화합물의 합성 방법
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CZ20032831A3 (cs) 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
CN100444839C (zh) 2002-03-18 2008-12-24 先灵公司 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用
MY144657A (en) 2004-01-30 2011-10-31 Schering Corp Crystalline polymorphs of a cxc-chemokine receptor ligand.
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
KR20070104460A (ko) 2005-02-10 2007-10-25 와커 헤미 아게 보호된 이소시아네이트기를 가지는 입자를 함유하는 래커
CN101203509B (zh) 2005-02-16 2013-05-08 默沙东公司 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
EP2041107A1 (en) 2006-07-07 2009-04-01 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
CA2680177A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
MX2009013276A (es) 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
CN101932553A (zh) 2007-07-03 2010-12-29 先灵公司 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体
CA2694268A1 (en) 2007-07-05 2009-01-08 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
WO2009073683A2 (en) 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
DK2307376T3 (en) 2008-08-04 2016-01-11 Merck Patent Gmbh NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508891A (ja) * 2001-01-30 2006-03-16 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 治療上有効な成分の長期放出／持続放出のための医薬組成物
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
WO2010015613A1 (en) * 2008-08-04 2010-02-11 Novartis Ag Organic compounds
WO2010057036A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof

Also Published As

Publication number Publication date
ES2655942T3 (es) 2018-02-22
EP2760821B1 (en) 2017-10-11
EA201490552A1 (ru) 2014-11-28
KR20140059264A (ko) 2014-05-15
US9018261B2 (en) 2015-04-28
JP6612200B2 (ja) 2019-11-27
PL2760821T3 (pl) 2018-04-30
CA2846510C (en) 2019-10-22
MX359259B (es) 2018-09-20
SI2760821T1 (en) 2018-02-28
EP2760821A1 (en) 2014-08-06
PT2760821T (pt) 2018-01-11
IN2014DN02346A (enExample) 2015-05-15
HUE035751T2 (hu) 2018-08-28
MX2014002492A (es) 2014-05-28
WO2013030803A1 (en) 2013-03-07
JP2017025081A (ja) 2017-02-02
EP3287438A1 (en) 2018-02-28
CA2846510A1 (en) 2013-03-07
BR112014004963A2 (pt) 2017-03-21
US20140206768A1 (en) 2014-07-24
JP2019001787A (ja) 2019-01-10
KR102024955B1 (ko) 2019-09-24
CN103842330B (zh) 2016-10-19
NO2679622T3 (enExample) 2018-01-20
CN103842330A (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
JP6612200B2 (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
US20250144112A1 (en) Suspension for oral administration comprising amorphous tolvaptan
CN114306245A (zh) 无定形固体分散体的药物组合物及其制备方法
US20180000792A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
WO2017153958A1 (en) Novel polymorphic forms and amorphous form of olaparib
TW202341973A (zh) 治療性化合物、調配物、及其用途
TW202200123A (zh) 一種複合物的藥物組合物及其製備方法
KR101093781B1 (ko) ｐＨ조절제를 함유하는 목시플록사신 고형 조성물
KR20210152280A (ko) 몬테루카스트와 레보세티리진을 포함하는 안정성이 향상된 단일 정제 및 이의 제조방법
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
EP3981469A1 (en) Therapeutic for gout or hyperuricemia
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof
EP4505999A1 (en) Probenecid formulations
AU2012303675A1 (en) Choline salt of an anti - inflammatory substituted cyclobutenedione compound
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
WO2024211881A1 (en) Rimegepant suspension
WO2025122075A1 (en) Pharmaceutical compositions of riociguat
HK40089965A (zh) 口服用药物组合物及其制备方法
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
HK1225281B (zh) 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1，2，3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140804

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160510